Sun Pharma.Inds.

What is the bonus history of the Sun Pharma.Inds.?

Sun Pharmaceutical Industries Ltd issued a 1:1 bonus on July 29, 2013, with a record date of July 30, 2013, allowing shareholders to double their holdings.

Sun Pharmaceutical Industries Ltd has a bonus history that includes a 1:1 bonus issue announced on July 29, 2013. The record date for this bonus was July 30, 2013. This means that for every share held, shareholders received an additional share, effectively doubling their holdings at that time. If you have any more questions about Sun Pharma or need further details, feel free to ask!

Is Sun Pharma.Inds. overvalued or undervalued?

As of May 23, 2025, Sun Pharmaceutical Industries Ltd. is considered overvalued with a PE ratio of 35.25 and a valuation grade of expensive, despite strong fundamentals, as it has underperformed the Sensex with a year-to-date return of -10.51%.

As of 23 May 2025, the valuation grade for Sun Pharmaceutical Industries Ltd. has moved from very expensive to expensive, indicating a slight improvement in perceived value but still reflecting a high valuation. The company is currently considered overvalued, with a PE ratio of 35.25, a Price to Book Value of 5.58, and an EV to EBITDA of 24.91. <BR><BR>In comparison to peers, Sun Pharma's PE ratio is higher than that of its competitor, which has a PE of approximately 30. This suggests that Sun Pharma is priced at a premium relative to its industry peers. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -10.51% compared to the Sensex's 5.58%. Overall, while there are strong fundamentals such as a ROCE of 25.60% and a ROE of 15.83%, the current valuation metrics indicate that Sun Pharma is overvalued in the market.

Who are the peers of the Sun Pharma.Inds.?

Sun Pharma.Inds. peers include Divi's Lab., Cipla, Torrent Pharma, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., Lupin, Abbott India, Aurobindo Pharma, and Glenmark Pharma. Divi's Lab. leads in 1-year returns at 49.58%, while Aurobindo Pharma has the lowest at -16.00%; Sun Pharma.Inds. has a 1-year return of 7.67%.

Peers: The peers of Sun Pharma.Inds. are Divi's Lab., Cipla, Torrent Pharma, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., Lupin, Abbott India, Aurobindo Pharma, and Glenmark Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Divi's Lab., Cipla, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., Abbott India, and the rest. Good growth is noted at Sun Pharma.Inds., Cipla, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., and the rest, while Below Average growth is found at Divi's Lab., Torrent Pharma, Aurobindo Pharma, and the rest. Excellent capital structure is seen at Divi's Lab., Cipla, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., Abbott India, Aurobindo Pharma, and the rest, while Good capital structure is noted at Torrent Pharma and Lupin, and Average capital structure is found at Lupin and Glenmark Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 49.58%, while Aurobindo Pharma has the lowest at -16.00%. Sun Pharma.Inds. has a 1-year return of 7.67%, which is higher than Aurobindo Pharma but lower than Divi's Lab. Additionally, Zydus Lifesci., Dr Reddy's Labs, and Lupin have negative six-month returns.

Who are in the management team of Sun Pharma.Inds.?

As of March 2022, the management team of Sun Pharma.Inds. includes Dilip S Shanghvi (Managing Director), Sudhir V Valia, Sailesh T Desai, Gautam Doshi, Pawan Goenka, Rama Bijapurkar, Anoop Deshpande (Company Secretary), Sanjay K Asher, Rolf Hoffmann, and Aalok Shanghvi (Whole-time Director), overseeing the company's strategic direction.

As of March 2022, the management team of Sun Pharma.Inds. includes the following individuals:<BR><BR>1. **Dilip S Shanghvi** - Managing Director<BR>2. **Sudhir V Valia** - Non-Executive & Non-Independent Director<BR>3. **Sailesh T Desai** - Whole-time Director<BR>4. **Gautam Doshi** - Non-Executive & Independent Director<BR>5. **Pawan Goenka** - Lead Independent Director<BR>6. **Rama Bijapurkar** - Independent Director<BR>7. **Anoop Deshpande** - Company Secretary & Compliance Officer<BR>8. **Sanjay K Asher** - Independent Director<BR>9. **Rolf Hoffmann** - Independent Director<BR>10. **Aalok Shanghvi** - Whole-time Director<BR><BR>This team is responsible for the strategic direction and management of the company.

What does Sun Pharma.Inds. do?

Sun Pharmaceutical Industries Ltd is a leading global specialty generic pharmaceutical company, the largest in India, with recent net sales of ₹129,588 Cr and a net profit of ₹21,499 Cr as of March 2025. It has a market cap of ₹414,857 Cr and key metrics include a P/E ratio of 36.00 and a dividend yield of 0.93%.

Overview:<BR>Sun Pharmaceutical Industries Ltd is a large-cap company in the Pharmaceuticals & Biotechnology industry, recognized as the fourth largest global specialty generic company.<BR><BR>History:<BR>Sun Pharmaceutical Industries Ltd was incorporated in 1993 and has since established itself as the largest Indian pharmaceutical company in the US. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 129,588 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 21,499 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 414,857 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 36.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.93% <BR>Debt-Equity: -0.31 <BR>Return on Equity: 15.83% <BR>Price to Book: 5.74<BR><BR>Contact Details:<BR>Address: Sun Pharma Advanced Res.Centre, Tandalja Vadodara Gujarat : 390020 <BR>Phone: 91-265-6615500 <BR>Email: secretarial@sunpharma.com <BR>Website: http://www.sunpharma.com

Who are the top shareholders of the Sun Pharma.Inds.?

The top shareholders of Sun Pharma.Inds. include Shanghvi Finance Private Limited (40.3%), institutional investors like mutual funds (12.21%) and FIIs (17.96%), with ICICI Prudential Value Discovery Fund as the largest public shareholder (3.35%), while individual investors hold 5.42%. This indicates strong support from both promoters and institutional investors.

The top shareholders of Sun Pharma.Inds. include a mix of promoters, institutional investors, and individual shareholders. The majority of the shares are held by promoters, with Shanghvi Finance Private Limited being the largest promoter, holding 40.3% of the company. <BR><BR>In terms of institutional holdings, mutual funds account for 12.21% of the shares, with 44 different schemes involved. Foreign Institutional Investors (FIIs) hold 17.96% of the company, represented by 1206 FIIs. The highest public shareholder is ICICI Prudential Value Discovery Fund, which holds 3.35%. Additionally, individual investors collectively hold 5.42% of the shares. <BR><BR>This diverse shareholder structure reflects a strong backing from both promoters and institutional investors.

How big is Sun Pharma.Inds.?

As of 24th July, Sun Pharmaceutical Industries Ltd has a market capitalization of 403,712.00 Cr, with recent net sales of 52,578.44 Cr and net profit of 10,929.04 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Sun Pharmaceutical Industries Ltd has a market capitalization of 403,712.00 Cr, classified as Large Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 52,578.44 Cr, while the sum of Net Profit for the same period is 10,929.04 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025. Shareholder's Funds amount to 72,218.02 Cr, and Total Assets are valued at 87,693.03 Cr.

Is Sun Pharma.Inds. technically bullish or bearish?

As of December 1, 2025, the trend is mildly bullish due to a bullish MACD and daily moving average, but caution is warranted from mixed signals in longer-term indicators.

As of 1 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly timeframe and a bullish daily moving average. However, the monthly MACD and KST are mildly bearish, indicating some caution. The Bollinger Bands show a mildly bullish trend on the weekly, while the Dow Theory supports a mildly bullish outlook on both weekly and monthly timeframes. Overall, the strength of the bullish sentiment is tempered by mixed signals in the longer-term indicators.

How has been the historical performance of Sun Pharma.Inds.?

Sun Pharma.Inds. has shown consistent growth from March 2019 to March 2025, with net sales increasing from 29,065.91 Cr to 52,578.44 Cr, and profit after tax rising from 3,209.32 Cr to 10,980.10 Cr. The company has also improved its operating profit margin and cash flow, indicating strong financial health.

Answer:<BR>The historical performance of Sun Pharma.Inds. shows a consistent growth trajectory in key financial metrics over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Sun Pharma.Inds. has demonstrated significant growth in net sales, increasing from 29,065.91 Cr in March 2019 to 52,578.44 Cr in March 2025. Total operating income has followed a similar upward trend, reaching 52,578.44 Cr in March 2025, up from 29,065.91 Cr in March 2019. The company's operating profit (PBDIT) has also improved markedly, rising from 7,333.08 Cr in March 2019 to 17,236.73 Cr in March 2025, reflecting a robust operating profit margin of 29.35% in the latest fiscal year. Profit before tax has surged to 13,752.13 Cr in March 2025, compared to 3,810.20 Cr in March 2019, while profit after tax reached 10,980.10 Cr, up from 3,209.32 Cr in March 2019. The company's total assets have increased from 65,077.17 Cr in March 2020 to 87,693.03 Cr in March 2025, indicating strong asset growth. Total liabilities have also risen, from 65,077.17 Cr in March 2020 to 87,693.03 Cr in March 2025, with total debt decreasing from 7,578.30 Cr in March 2020 to 1,869.63 Cr in March 2025. Cash flow from operating activities has improved significantly, reaching 14,072.00 Cr in March 2025, compared to 6,554.00 Cr in March 2020, contributing to a closing cash and cash equivalent of 10,268.00 Cr in March 2025. Overall, Sun Pharma.Inds. has shown a strong upward trend in revenue, profitability, and cash flow, positioning itself favorably in the market.

When is the next results date for Sun Pharmaceutical Industries Ltd?

The next results date for Sun Pharmaceutical Industries Ltd is January 31, 2026.

The next results date for Sun Pharmaceutical Industries Ltd is scheduled for January 31, 2026.

Are Sun Pharmaceutical Industries Ltd latest results good or bad?

Sun Pharmaceutical Industries Ltd's latest Q3 FY26 results are positive, with a net profit of ₹3,368.81 crores, reflecting an 8.05% QoQ and 16.03% YoY increase, alongside net sales growth of 7.20% QoQ and 13.49% YoY. The improved operating margin of 31.99% indicates strong demand and effective cost management.

Sun Pharmaceutical Industries Ltd's latest results for Q3 FY26 can be considered quite positive. The company reported a net profit of ₹3,368.81 crores, which reflects an increase of 8.05% quarter-on-quarter (QoQ) and a significant 16.03% year-on-year (YoY) growth. Additionally, net sales reached ₹15,520.54 crores, marking a 7.20% increase QoQ and a 13.49% increase YoY, indicating strong demand across both domestic and international markets.<BR><BR>The operating margin also improved, reaching 31.99%, which is a sequential increase from the previous quarter. This margin expansion, along with a profit after tax margin of 21.99%, demonstrates the company's effective cost management and operational efficiency.<BR><BR>Overall, the financial performance highlights Sun Pharma's ability to sustain momentum and capitalize on growth opportunities, making the latest results favorable for the company.

Has Sun Pharmaceutical Industries Ltd declared dividend?

Yes, Sun Pharmaceutical Industries Ltd has declared a dividend of 1100% (₹5.5 per share), with an ex-date of February 5, 2026. While recent short-term returns have been negative, the company has shown strong growth over longer periods.

Sun Pharmaceutical Industries Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1100%<BR>- Amount per share: 5.5<BR>- Ex-date: 05 Feb 26<BR><BR>Dividend Yield: 1%<BR><BR>Total Returns by Period:<BR>In the 3-month period, the price return was -5.48%, the dividend return was 0.65%, resulting in a total return of -4.83%.<BR><BR>In the 6-month period, the price return was -7.19%, the dividend return was 0.67%, leading to a total return of -6.52%.<BR><BR>For the 1-year period, the price return was -7.74%, the dividend return was 0.95%, culminating in a total return of -6.79%.<BR><BR>Over the 2-year period, the price return was 17.4%, the dividend return was 2.09%, resulting in a total return of 19.49%.<BR><BR>In the 3-year period, the price return was 53.22%, the dividend return was 4.52%, leading to a total return of 57.74%.<BR><BR>For the 4-year period, the price return was 94.64%, the dividend return was 6.50%, culminating in a total return of 101.14%.<BR><BR>In the 5-year period, the price return was 174.57%, the dividend return was 10.59%, resulting in a total return of 185.16%.<BR><BR>Overall, Sun Pharmaceutical Industries Ltd has declared a significant dividend, and while recent short-term returns have been negative, the longer-term returns indicate strong growth and positive performance over the years.

Should I buy, sell or hold Sun Pharmaceutical Industries Ltd?

Why is Sun Pharmaceutical Industries Ltd falling/rising?

As of 17-Mar, Sun Pharmaceutical Industries Ltd's stock price is rising to 1,790.70, reflecting a trend reversal after previous declines and nearing its 52-week high. Strong fundamentals and outperformance against the Sensex support this increase, despite a decline in investor participation.

As of 17-Mar, Sun Pharmaceutical Industries Ltd's stock price is rising, currently at 1,790.70, reflecting an increase of 8.15 (0.46%). This upward movement follows a trend reversal after two consecutive days of decline. The stock is also close to its 52-week high, being only 3.36% away from Rs 1,850.95. <BR><BR>In terms of performance, the stock has shown resilience over the past month, gaining 4.27% while the benchmark Sensex has fallen by 8.84%. Year-to-date, it has outperformed the Sensex, with a gain of 4.13% compared to the index's decline of 10.74%. Over the past year, the stock has increased by 5.03%, while the Sensex has only risen by 2.56%. <BR><BR>The company's strong fundamentals contribute to this positive sentiment. It has a low debt-to-equity ratio, healthy long-term growth in net sales, and a solid return on equity, indicating high profitability. Additionally, the company has declared positive results for the last three consecutive quarters, which bolsters investor confidence. <BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 25.17% against the 5-day average. Despite this, the stock remains liquid enough for trading, which suggests that the current rise may be supported by institutional holdings, which stand at 36.94%. <BR><BR>Overall, the combination of strong financial performance, a favorable trend reversal, and relative outperformance against the benchmark are key factors contributing to the rise in Sun Pharmaceutical Industries Ltd's stock price.

Why is Sun Pharmaceutical Industries Ltd falling/rising?

As of 18-Mar, Sun Pharmaceutical Industries Ltd's stock price is at 1,780.00, down 0.87%. The decline is due to recent underperformance, reduced investor participation, and a high valuation, despite the company's strong long-term fundamentals.

As of 18-Mar, Sun Pharmaceutical Industries Ltd's stock price is currently at 1,780.00, reflecting a decrease of 15.6 points or 0.87%. The decline in the stock price can be attributed to several factors. Firstly, over the past week, the stock has underperformed with a return of -2.46%, compared to a minor decline of -0.21% in the Sensex. Additionally, the stock has shown a negative performance today, underperforming its sector by 1.14%.<BR><BR>Investor participation appears to be waning, as evidenced by a significant drop in delivery volume, which fell by 20.13% against the 5-day average. This decline in trading activity may indicate reduced investor confidence or interest in the stock at its current price level. <BR><BR>Despite these negative indicators, it is worth noting that the company has strong long-term fundamentals, including a low debt-to-equity ratio and consistent growth in net sales and operating profit. However, the stock's current valuation is considered expensive, with a Price to Book Value of 5.5, which may deter some investors. <BR><BR>Overall, the combination of recent underperformance, declining investor participation, and high valuation relative to peers contributes to the current downward movement in Sun Pharmaceutical Industries Ltd's stock price.

Why is Sun Pharmaceutical Industries Ltd falling/rising?

As of 19-Mar, Sun Pharmaceutical Industries Ltd's stock price is 1,744.35, down 1.93% due to selling pressure and a broader decline in the Pharmaceuticals & Drugs sector. Despite outperforming its sector slightly, overall market sentiment remains bearish.

As of 19-Mar, Sun Pharmaceutical Industries Ltd is experiencing a decline in its stock price, currently at 1,744.35, which reflects a change of -34.4 or -1.93%. This drop can be attributed to several factors. The stock has been on a consecutive fall for the last two days, resulting in a total decline of -2.37% during this period. Additionally, the stock touched an intraday low of Rs 1737.7, indicating significant selling pressure.<BR><BR>In terms of broader market performance, the Pharmaceuticals & Drugs sector has also seen a decrease of -2.11%, which may have contributed to the stock's downward movement. Furthermore, there has been a decline in investor participation, with delivery volume falling by -1.06% compared to the five-day average, suggesting reduced interest from investors.<BR><BR>Despite these negative trends, it is noteworthy that Sun Pharmaceutical has outperformed its sector by 0.7% today, indicating some resilience. However, the overall sentiment appears to be bearish, as reflected in the stock's recent performance and the broader market conditions.

Why is Sun Pharmaceutical Industries Ltd falling/rising?

As of 20-Mar, Sun Pharmaceutical Industries Ltd's stock price has risen to 1,777.20, reflecting a 1.88% increase after a trend reversal. Strong fundamentals, positive investor sentiment, and high institutional holdings are driving this upward movement.

As of 20-Mar, Sun Pharmaceutical Industries Ltd is experiencing a rise in its stock price, currently at 1,777.20, which reflects an increase of 32.85 (1.88%). This upward movement follows a trend reversal after two consecutive days of decline. The stock has shown resilience, gaining 3.06% over the past month, while the benchmark Sensex has declined by 10.00% during the same period. Furthermore, the stock has outperformed the Sensex year-to-date, with a gain of 3.34% compared to the Sensex's drop of 12.54%.<BR><BR>The stock is also close to its 52-week high, being only 4.15% away from Rs 1,850.95. Today's performance aligns with sector trends, and the stock reached an intraday high of Rs 1,781.6, marking a 2.14% increase. Despite a decrease in investor participation, as indicated by a 14.09% drop in delivery volume compared to the 5-day average, the stock remains liquid enough for trading.<BR><BR>Positive factors contributing to the stock's rise include the company's strong long-term fundamentals, such as a healthy annual growth rate in net sales of 11.37% and operating profit growth of 20.79%. Additionally, the company has maintained a low debt-to-equity ratio and has consistently generated a return on equity of 15.21%. The company has also reported positive results for the last three consecutive quarters, further bolstering investor confidence.<BR><BR>Moreover, high institutional holdings at 36.94% suggest that knowledgeable investors are backing the stock, which can positively influence its price. The company's significant market capitalization of Rs 4,20,603 crore, constituting 18.38% of the sector, along with consistent returns over the past three years, reinforces its position in the market.<BR><BR>In summary, the combination of a recent trend reversal, strong fundamentals, and positive investor sentiment are key factors driving the rise in Sun Pharmaceutical Industries Ltd's stock price.

Why is Sun Pharmaceutical Industries Ltd falling/rising?

As of 23-Mar, Sun Pharmaceutical Industries Ltd's stock price is 1,756.35, down 1.19%, but it has outperformed the sector by 2.38%. Despite recent volatility and a slight year-over-year decline, the company shows strong fundamentals and increased investor interest.

As of 23-Mar, Sun Pharmaceutical Industries Ltd's stock price is currently at 1,756.35, reflecting a decrease of 21.1 points or 1.19%. The stock's performance today indicates it has outperformed the sector by 2.38%, despite the overall decline in the Pharmaceuticals & Drugs sector, which has fallen by 3.62%. <BR><BR>In terms of recent trends, the stock has shown a decline of 1.47% over the past week, while it has increased by 1.39% over the past month. Year-to-date, the stock has risen by 2.13%, contrasting with a significant drop of 14.70% in the sector. Over the last year, however, the stock has experienced a slight decline of 1.54%, while the Sensex has also decreased by 5.47%.<BR><BR>The stock's current price is higher than its 50-day, 100-day, and 200-day moving averages, but lower than its 5-day and 20-day moving averages, indicating some short-term volatility. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 59.63% against the 5-day average, suggesting a growing interest in the stock despite its current price decline.<BR><BR>On the positive side, Sun Pharmaceutical has demonstrated strong long-term fundamentals, including a healthy growth rate in net sales and operating profit, alongside a low debt-to-equity ratio. The company has also reported positive results for the last three consecutive quarters, which may support its long-term value. However, the stock is considered expensive relative to its peers, with a high price-to-book value and a PEG ratio of 11.8, which could contribute to the downward pressure on its price as investors weigh these factors against its recent performance.

Why is Sun Pharmaceutical Industries Ltd falling/rising?

As of 24-Mar, Sun Pharmaceutical Industries Ltd's stock price is slightly rising to 1,756.80, driven by strong long-term fundamentals and increased investor participation. Despite underperforming its sector and trading at a premium, the company's financial stability and positive quarterly results support this upward trend.

As of 24-Mar, Sun Pharmaceutical Industries Ltd's stock price is experiencing a slight rise, currently at 1,756.80, with a change of 0.45 (0.03%) upward. This modest increase can be attributed to several factors. <BR><BR>Firstly, the company has demonstrated strong long-term fundamental strength, with net sales growing at an annual rate of 11.37% and operating profit at 20.79%. Additionally, Sun Pharmaceutical has a low debt-to-equity ratio, averaging 0 times, which indicates financial stability. The company has also reported positive results for the last three consecutive quarters, showcasing a healthy inventory turnover ratio and significant cash reserves.<BR><BR>Moreover, there has been rising investor participation, with a delivery volume of 20.15 lacs on 23 March, which is an 18.06% increase compared to the 5-day average. This suggests that more investors are willing to hold onto the stock, reflecting confidence in its future performance.<BR><BR>However, it is important to note that the stock has underperformed its sector by 1.09% today and is trading at a premium compared to its peers, with a price-to-book value of 5.4. Despite these challenges, the overall positive fundamentals and increasing investor interest are contributing to the stock's current upward movement.

Why is Sun Pharmaceutical Industries Ltd falling/rising?

As of 25-Mar, Sun Pharmaceutical Industries Ltd's stock price has risen to Rs 1,803.00, reflecting a 2.86% increase. This rise is driven by a trend reversal, strong performance metrics, and solid fundamentals, despite a recent decline in investor participation.

As of 25-Mar, Sun Pharmaceutical Industries Ltd is experiencing a rise in its stock price, currently at Rs 1,803.00, which reflects an increase of Rs 50.2 or 2.86%. This upward movement can be attributed to several factors highlighted in the data. <BR><BR>Firstly, the stock has shown a trend reversal, gaining after two consecutive days of decline. Additionally, it has outperformed its sector by 0.97% today, indicating strong relative performance. The stock also reached an intraday high of Rs 1,809.55, which is 3.24% higher than its previous close, suggesting positive momentum.<BR><BR>Moreover, Sun Pharmaceutical is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bullish trend. The company has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 11.37% and operating profit at 20.79%. Its low debt-to-equity ratio and strong return on equity further bolster investor confidence.<BR><BR>Despite a recent decline in investor participation, as indicated by a 17.07% drop in delivery volume compared to the 5-day average, the overall fundamentals remain strong. The company has declared positive results for the last three consecutive quarters, with significant metrics such as the highest inventory turnover ratio and cash equivalents, which enhance its attractiveness to investors.<BR><BR>In summary, the combination of a trend reversal, strong performance metrics, and solid fundamentals contributes to the rising stock price of Sun Pharmaceutical Industries Ltd.

Which are the latest news on Sun Pharma.Inds.?